Glycine Signaling in the Framework of Dopamine-Glutamate Interaction and Postsynaptic Density. Implications for Treatment-Resistant Schizophrenia
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Treatment-resistant schizophrenia (TRS) or suboptimal response to antipsychotics affects almost 30% of schizophrenia (SCZ) patients, and it is a relevant clinical issue with significant impact on the functional outcome and on the global burden of disease. Among putative novel treatments, glycine-centered therapeutics (i.e. sarcosine, glycine itself, D-Serine, and bitopertin) have been proposed, based on a strong preclinical rationale with, however, mixed clinical results. Therefore, a better appraisal of glycine interaction with the other major players of SCZ pathophysiology and specifically in the framework of dopamine - glutamate interactions is warranted. New methodological approaches at cutting edge of technology and drug discovery have been applied to study the role of glycine in glutamate signaling, both at presynaptic and post-synaptic level and have been instrumental for unveiling the role of glycine in dopamine-glutamate interaction. Glycine is a non-essential amino acid that plays a critical role in both inhibitory and excitatory neurotransmission. In caudal areas of central nervous system (CNS), such as spinal cord and brainstem, glycine acts as a powerful inhibitory neurotransmitter through binding to its receptor, i.e. the Glycine Receptor (GlyR). However, glycine also works as a co-agonist of the N-Methyl-D-Aspartate receptor (NMDAR) in excitatory glutamatergic neurotransmission. Glycine concentration in the synaptic cleft is finely tuned by glycine transporters, i.e. GlyT1 and GlyT2, that regulate the neurotransmitter's reuptake, with the first considered a highly potential target for psychosis therapy. Reciprocal regulation of dopamine and glycine in forebrain, glycine modulation of glutamate, glycine signaling interaction with postsynaptic density proteins at glutamatergic synapse, and human genetics of glycinergic pathways in SCZ are tackled in order to highlight the exploitation of this neurotransmitters and related molecules in SCZ and TRS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
NMDA receptor subunits: diversity, development and disease
Cull-Candy, S., Brickley, S., & Farrant, M. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00215-4 · Cited by 1,694
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“Furthermore, NMDAR antagonists may affect widespread neuropsychological domains: working memory, response inhibition, and executive processing, resulting in cognitive symptoms that are also described in SCZ, suggesting the involvement of glutamatergic neurotransmission in the pathogenetic mechanism underlying psychoti…”
BackgroundBreier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 1×
“Neuroimaging studies using positron emission (PET) or single photon emission (SPECT) demonstrated that, after acute amphetamine administration, patients with SCZ showed greater levels of dopamine release in subcortical regions (particularly in the striatum) compared to healthy subjects, and displayed a transient worse…”
BackgroundDysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring
Stephan, K. E., Friston, K. J., & Frith, C. D. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn176 · Cited by 1,134 · cited 1×
“SCZ is nowadays conceptualized at molecular level as a disorder of the synaptic plasticity (2) and of abnormal cortical-subcortical connectivity (3–5).”
BackgroundMice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075
Glia-Derived d-Serine Controls NMDA Receptor Activity and Synaptic Memory
Panatier, A., Theodosis, D. T., Mothet, J.-P., Touquet, B., Pollegioni, L., Poulain, D. A., & Oliet, S. H. R. (2006) · Cell · doi:10.1016/j.cell.2006.02.051 · Cited by 934
Seeman, P., & Lee, T. (1975) · Science · doi:10.1126/science.1145194 · Cited by 869 · cited 1×
“This hypothesis holds that hyperactivity of dopamine transmission is responsible for positive symptoms (1) and it was formulated in the 1960s, after the discovery of antipsychotic action of chlorpromazine (33), and further endorsed by the correlation between clinical response to antipsychotic drugs and their potency t…”
BackgroundPostnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes
Belforte, J. E., Zsiros, V., Sklar, E. R., Jiang, Z., Yu, G., Li, Y., Quinlan, E. M., & Nakazawa, K. (2010) · Nature Neuroscience · doi:10.1038/nn.2447 · Cited by 752
NMDA receptors, place cells and hippocampal spatial memory
Nakazawa, K., McHugh, T. J., Wilson, M. A., & Tonegawa, S. (2004) · Nature Reviews Neuroscience · doi:10.1038/nrn1385 · Cited by 619 · cited 2×
“As an excitatory neurotransmitter, glycine acts as a co-agonist of NMDAR, allowing for depolarization, removal of the magnesium blockade and Na/Ca2 passage through the channel, which ultimately enhances the glutamatergic excitatory tone that is critical for learning and neuronal plasticity (44, 45).”
BackgroundIncreased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Altering the course of schizophrenia: progress and perspectives
Millan, M. J., Andrieux, A., Bartzokis, G., Cadenhead, K., Dazzan, P., Fusar-Poli, P., Gallinat, J., Giedd, J., Grayson, D. R., Heinrichs, M., et al. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.28 · Cited by 516
GABAergic interneuron origin of schizophrenia pathophysiology
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., & Belforte, J. E. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.022 · Cited by 498 · cited 2×
“The activation of GABAergic interneurons by glutamatergic projections is mediated by NMDAR, and NMDARhypofunction may specifically affect corticolimbic GABAergic parvalbumin-positive (PV+) interneurons, reducing their excitability and expression of specific molecular markers such as somatostatin and vasoactive intesti…”
BackgroundSchell, M. J., Brady Jr., R. O., Molliver, M. E., & Snyder, S. H. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01604.1997 · Cited by 415 · cited 1×
“Immunohistochemical studies comparing D-serine, glycine, and NMDARs pattern of distribution in rat brain, showed that D-serine and NMDARs overlap each other and have the highest concentration in telencephalon and developing cerebellum; conversely, glycine immunoreactivity does not correspond to NMDARs localization (ex…”
BackgroundThe social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392
Glutamate induces de novo growth of functional spines in developing cortex
Kwon, H.-B., & Sabatini, B. L. (2011) · Nature · doi:10.1038/nature09986 · Cited by 368
Increased stress-induced dopamine release in psychosis
Mizrahi, R., Addington, J., Rusjan, P. M., Suridjan, I., Ng, A., Boileau, I., Pruessner, J. C., Remington, G., Houle, S., & Wilson, A. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.009 · Cited by 277
Distinct Roles of NR2A and NR2B Cytoplasmic Tails in Long-Term Potentiation
Foster, K. A., McLaughlin, N., Edbauer, D., Phillips, M., Bolton, A., Constantine-Paton, M., & Sheng, M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4022-09.2010 · Cited by 219
Grabrucker, S., Jannetti, L., Eckert, M., Gaub, S., Chhabra, R., Pfaender, S., Mangus, K., Reddy, P. P., Rankovic, V., Schmeisser, M. J., et al. (2014) · Brain · doi:10.1093/brain/awt303 · Cited by 175
Why glycine transporters have different stoichiometries
Supplisson, S., & Roux, M. J. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03251-9 · Cited by 122 · cited 1×
“GlyT1 works in a bidirectional fashion with a stoichiometry of 2Na/Cl/Gly, regulating glycine availability in the extracellular space, and terminates glycine signaling (134), significantly modulating the glutamatergic neurotransmission.”
BackgroundPrata, J., Santos, S. G., Almeida, M. I., Coelho, R., & Barbosa, M. A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0938-y · Cited by 115
Genetic and functional analyses demonstrate a role for abnormal glycinergic signaling in autism
Pilorge, M., Fassier, C., Le Corronc, H., Potey, A., Bai, J., De Gois, S., Delaby, E., Assouline, B., Guinchat, V, Devillard, F., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.139 · Cited by 110 · cited 4×
“As highlighted by genetic and functional studies, suggesting the potential role of a2 GlyRs in synaptic plasticity, as well as learning and memory, glycinergic May 2020 | Volume 11 | Article 369 signaling might be linked to social and cognitive abnormalities in ASD (127).”
BackgroundInfluentialAn integrative framework for perceptual disturbances in psychosis
Horga, G., & Abi-Dargham, A. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0234-1 · Cited by 103
Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86
Li, Y., Sacchi, S., Pollegioni, L., Basu, A. C., Coyle, J. T., & Bolshakov, V. Y. (2013) · Nature Communications · doi:10.1038/ncomms2779 · Cited by 82 · cited 2×
“Therefore, ambient D-serine may act as major ligand in absence of evoked synaptic events, while activity-dependent release of glycine may be involved in LTP-related NMDAR activation in the context of fear conditioning pathways (91).”
BackgroundResultKrystal, J. H., Tolin, D. F., Sanacora, G., Castner, S. A., Williams, G. V., Aikins, D. E., Hoffman, R. E., & D'Souza, D. C. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.05.002 · Cited by 76
de Bartolomeis, A., Buonaguro, E. F., Latte, G., Rossi, R., Marmo, F., Iasevoli, F., & Tomasetti, C. (2017) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2017.00240 · Cited by 44
Self-citation
Cited by
Gut Bacteria and Neurotransmitters
Dicks, L. M. T. (2022) · Microorganisms · doi:10.3390/microorganisms10091838 · Cited by 482
de Bartolomeis, A., Barone, A., Vellucci, L., Mazza, B., Austin, M. C., Iasevoli, F., & Ciccarelli, M. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02976-3 · Cited by 113
Self-citationDe Simone, G., Mazza, B., Vellucci, L., Barone, A., Ciccarelli, M., & de Bartolomeis, A. (2023) · Antioxidants · doi:10.3390/antiox12040975 · Cited by 49
Self-citation
Metadata
- Authors
- de Bartolomeis, A., Manchia, M., Marmo, F., Vellucci, L., Iasevoli, F., & Barone, A.
- Venue
- Frontiers in Psychiatry
- Publisher
- Frontiers Media SA
- Published
- 2020-05-14
- Volume
- 11
- Pages
- 369-369
- ISSN
- 1664-0640 (ISSN-L)
- OpenAlex
- W3024472781
- Cited by
- 53
- References
- 28
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.